Related references
Note: Only part of the references are listed.Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia
Wai Kien Yip et al.
APMIS (2013)
High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer
Joana G. Guedes et al.
BMC CANCER (2013)
Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery
Olfa Derbel et al.
BMC CANCER (2013)
Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit
Hideaki Bando et al.
BMC CANCER (2013)
Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab
Christopher G. Smith et al.
CLINICAL CANCER RESEARCH (2013)
Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer
Hiroshi Soeda et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2013)
Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer
Ryota Nakanishi et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2013)
KRAS gene mutations in correlation with clinicopathological features of colorectal carcinomas in Indian patient cohort
Harshali Patil et al.
MEDICAL ONCOLOGY (2013)
Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients
Grigoriy A. Yanus et al.
MEDICAL ONCOLOGY (2013)
PIK3CA Activating Mutation in Colorectal Carcinoma: Associations with Molecular Features and Survival
Christophe Rosty et al.
PLOS ONE (2013)
Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians
Pooja Malhotra et al.
TUMOR BIOLOGY (2013)
Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis
Jens Neumann et al.
VIRCHOWS ARCHIV (2013)
PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
C. Mao et al.
ANNALS OF ONCOLOGY (2012)
Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population
Li-Ling Hsieh et al.
CLINICA CHIMICA ACTA (2012)
Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian colorectal cancer patients
Cristina Bozzao et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS (2012)
Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia
Grazia Palomba et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival
Xiaoyun Liao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
KRAS, BRAF and PIK3CA Mutations and the Loss of PTEN Expression in Chinese Patients with Colorectal Cancer
Chen Mao et al.
PLOS ONE (2012)
Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma
Sarita B. Bagadi et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS (2012)
Alterations in PTEN and PIK3CA in colorectal cancers in the EPIC Norfolk study: associations with clinicopathological and dietary factors
Adam Naguib et al.
BMC CANCER (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Phosphorylated AKT Expression Is Associated With PIK3CA Mutation, Low Stage, and Favorable Outcome in 717 Colorectal Cancers
Yoshifumi Baba et al.
CANCER (2011)
Frequency of KRAS, BRAF, and NRAS Mutations in Colorectal Cancer
Cecily P. Vaughn et al.
GENES CHROMOSOMES & CANCER (2011)
Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2nd Line Cetuximab-Based Therapy of Colorectal Cancer Patients
Zacharenia Saridaki et al.
PLOS ONE (2011)
PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers
Filip Janku et al.
PLOS ONE (2011)
Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: Comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue
Mi Jung Kwon et al.
PATHOLOGY RESEARCH AND PRACTICE (2011)
Gene Mutations in Epidermal Growth Factor Receptor Signaling Network and Their Association With Survival in Chinese Patients With Metastatic Colorectal Cancers
Wangjun Liao et al.
ANATOMICAL RECORD-ADVANCES IN INTEGRATIVE ANATOMY AND EVOLUTIONARY BIOLOGY (2010)
Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer
F. Di Fiore et al.
BRITISH JOURNAL OF CANCER (2010)
Molecular Markers in the Treatment of Metastatic Colorectal Cancer
Peter M. Wilson et al.
CANCER JOURNAL (2010)
Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
Stephan E. Baldus et al.
CLINICAL CANCER RESEARCH (2010)
Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab
Jolien Tol et al.
EUROPEAN JOURNAL OF CANCER (2010)
Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer
Geraldine Perkins et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type
Stefano Barbi et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
Two Multiplex Assays That Simultaneously Identify 22 Possible Mutation Sites in the KRAS, BRAF, NRAS and PIK3CA Genes
Irene Lurkin et al.
PLOS ONE (2010)
DNA Sequence Profiles of the Colorectal Cancer Critical Gene Set KRAS-BRAF-PIK3CA-PTEN-TP53 Related to Age at Disease Onset
Marianne Berg et al.
PLOS ONE (2010)
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
F. Perrone et al.
ANNALS OF ONCOLOGY (2009)
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
J. Souglakos et al.
BRITISH JOURNAL OF CANCER (2009)
PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
Andrea Sartore-Bianchi et al.
CANCER RESEARCH (2009)
PIK3CA Mutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer
Shuji Ogino et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer
Salvatore Siena et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer
Jens Neumann et al.
PATHOLOGY RESEARCH AND PRACTICE (2009)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
NATURE REVIEWS CANCER (2009)
High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer
Lisa Simi et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2008)
BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer:: Primary or secondary genetic events in colorectal carcinogenesis?
Sergia Velho et al.
BMC CANCER (2008)
Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC
A. Kalikaki et al.
BRITISH JOURNAL OF CANCER (2008)
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
F. Cappuzzo et al.
BRITISH JOURNAL OF CANCER (2008)
Association of k-ras mutational status and clinical outcomes in patients with metastatic colorectal. cancer receiving panitumumab alone
Daniel J. Freeman et al.
CLINICAL COLORECTAL CANCER (2008)
Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers
Ludovic Barault et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms
Li Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit
Nabil Miled et al.
SCIENCE (2007)
Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model
Xiao-Ning Guo et al.
CANCER RESEARCH (2007)
Rare cancer-specific mutations in PIK3CA show gain of function
Marco Gymnopoulos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies
Silvia Benvenuti et al.
CANCER RESEARCH (2007)
The epidermal growth factor receptor pathway: A model for targeted therapy
Maurizio Scaltriti et al.
CLINICAL CANCER RESEARCH (2006)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA)
MR Sapio et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
Mutation analysis of p53, k-ras, and BRAF genes in colorectal cancer progression
D Calistri et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2005)
The prevalence of PIK3CA mutations in gastric and colon cancer
S Velho et al.
EUROPEAN JOURNAL OF CANCER (2005)
Mutant PIK3CA promotes cell growth and invasion of human cancer cells
Y Samuels et al.
CANCER CELL (2005)
Functional analysis of PIK3CA gene mutations in human colorectal cancer
T Ikenoue et al.
CANCER RESEARCH (2005)
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
SY Kang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
(Neo-)adjuvant treatments in colorectal cancer
D Arnold et al.
ANNALS OF ONCOLOGY (2005)
High frequency of mutations of the PIK3CA gene in human cancers
Y Samuels et al.
SCIENCE (2004)
Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas
K Fransén et al.
CARCINOGENESIS (2004)
The PIK3CA gene is mutated with high frequency in human breast cancers
KE Bachman et al.
CANCER BIOLOGY & THERAPY (2004)
Share Paper
